Proton pump inhibitors therapy and cyp2c19 gene variability in
Czech patients with gastroesophageal reflux disease: pilot
study

a 2017

Proton pump inhibitors therapy and cyp2c19 gene variability in Czech patients with gastroesophageal reflux disease: pilot study

BOŘILOVÁ LINHARTOVÁ, Petra, Ladislav BARTOŠ, Ladislava BARTOŠOVÁ, Adam KŘENEK, Jiří DOLINA et. al.

Basic information

Original name

Proton pump inhibitors therapy and cyp2c19 gene variability in Czech patients with gastroesophageal reflux disease: pilot study

Authors

BOŘILOVÁ LINHARTOVÁ, Petra (203 Czech Republic, belonging to the institution), Ladislav BARTOŠ (203 Czech Republic, belonging to the institution), Ladislava BARTOŠOVÁ (203 Czech Republic, belonging to the institution), Adam KŘENEK (203 Czech Republic), Jiří DOLINA (203 Czech Republic), Filip MAREK (203 Czech Republic), Zdeněk KALA (203 Czech Republic) and Lydie IZAKOVIČOVÁ HOLLÁ (203 Czech Republic, belonging to the institution)

Edition

67. Česko-Slovenské Farmakologické dni, 2017

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Slovakia

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/17:00095039

Organization unit

Faculty of Medicine

ISSN

Keywords in English

Proton pump inhibitors

Abstract

V originále

Proton pump inhibitors (PPIs) are a class of drugs used as the first-line therapy to treat gastroesophageal reflux disease (GERD). PPIs are metabolized mainly by cytochrome P450 2C19 (CYP2C19). The aim of the pilot study was to map the use of these drugs in Czech patients with various degrees of GERD and to analyze their individual variability in the gene encoding the CYP2C19. A total of 280 subjects (mean age±standard deviation: 46.23±13.11 years) were enrolled in the study: 95 patients with non-erosive reflux disease (NERD), 124 with reflux esophagitis (RE) and 61 with Barrett's esophagus (BE) or esophageal adenocarcinoma (EAC). The diagnosis was determined on the basis of clinical symptoms such as heartburn (pyrosis) and/or acid regurgitation; objectified with 24-h pH-metry, esophagogastroduodenoscopy and manometry. The determination of genotypes of two polymorphisms in the CYP2C19 gene (*17 rs12248560 and *2 rs4244285) was based on the principle of real-time polymerase chain reaction with TaqMan assays. Almost 90% patients with GERD took one or more PPIs (omeprazole, pantoprazole and/or lansoprazole). In addition, 37% patients took some prokinetics and 16.4% patients had polypragmasy. The results of haplogenotype analyses of the CYP2C19 gene classified 36.8% patients into a group of extensive metabolizers (*1*1/*1*1) or even ultrarapid metabolizers 37.2% (*1*1/*1*17 and *1*1/*17*17); only smaller numbers of patients were intermediate or poor metabolizers (17.1% or 1.4%, respectively). We concluded that the most common loss-of-function CYP2C19*2 and gain-of-function CYP2C19*17 variants should be examined in patients with GERD before PPI pharmacotherapy is prescribed. Selection of adequate drugs and their proper dosing may contribute to improve patients’s life quality and prevent the progression to more severe GERD conditions such as BE and EAC.

Links

GB14-37368G, research and development project

Name: Centrum orofaciálního vývoje a regenerace

Investor: Czech Science Foundation

MUNI/A/0948/2016, interní kód MU

Name: Nemoci dutiny ústní – etiopatogeneze, klinické projevy, diagnostika a léčba

Investor: Masaryk University, Category A

ROZV/25/LF/2017, interní kód MU

Name: LF - Příspěvek na IP 2017

Investor: Ministry of Education, Youth and Sports of the CR, Internal development projects

Citovat

BOŘILOVÁ LINHARTOVÁ, Petra, Ladislav BARTOŠ, Ladislava BARTOŠOVÁ, Adam KŘENEK, Jiří DOLINA, Filip MAREK, Zdeněk KALA and Lydie IZAKOVIČOVÁ HOLLÁ. Proton pump inhibitors therapy and cyp2c19 gene variability in Czech patients with gastroesophageal reflux disease: pilot study. In 67. Česko-Slovenské Farmakologické dni. 2017. ISSN 1337-6853.

@proceedings{1391617,
   author = {Bořilová Linhartová, Petra and Bartoš, Ladislav and Bartošová, Ladislava and Křenek, Adam and Dolina, Jiří and Marek, Filip and Kala, Zdeněk and Izakovičová Hollá, Lydie},
   booktitle = {67. Česko-Slovenské Farmakologické dni},
   keywords = {Proton pump inhibitors},
   language = {eng},
   title = {Proton pump inhibitors therapy and cyp2c19 gene variability in Czech patients with gastroesophageal reflux disease: pilot study},
   year = {2017}
}

TY  - CONF
ID  - 1391617
AU  - Bořilová Linhartová, Petra - Bartoš, Ladislav - Bartošová, Ladislava - Křenek, Adam - Dolina, Jiří - Marek, Filip - Kala, Zdeněk - Izakovičová Hollá, Lydie
PY  - 2017
TI  - Proton pump inhibitors therapy and cyp2c19 gene variability in Czech patients with gastroesophageal reflux disease: pilot study
KW  - Proton pump inhibitors
N2  - Proton pump inhibitors (PPIs) are a class of drugs used as the first-line therapy to treat gastroesophageal reflux disease (GERD). PPIs are metabolized mainly by cytochrome P450 2C19 (CYP2C19). The aim of the pilot study was to map the use of these drugs in Czech patients with various degrees of GERD and to analyze their individual variability in the gene encoding the CYP2C19. A total of 280 subjects (mean age±standard deviation: 46.23±13.11 years) were enrolled in the study: 95 patients with non-erosive reflux disease (NERD), 124 with reflux esophagitis (RE) and 61 with Barrett's esophagus (BE) or esophageal adenocarcinoma (EAC). The diagnosis was determined on the basis of clinical symptoms such as heartburn (pyrosis) and/or acid regurgitation; objectified with 24-h pH-metry, esophagogastroduodenoscopy and manometry. The determination of genotypes of two polymorphisms in the CYP2C19 gene (*17 rs12248560 and *2 rs4244285) was based on the principle of real-time polymerase chain reaction with TaqMan assays. Almost 90% patients with GERD took one or more PPIs (omeprazole, pantoprazole and/or lansoprazole). In addition, 37% patients took some prokinetics and 16.4% patients had polypragmasy. The results of haplogenotype analyses of the CYP2C19 gene classified 36.8% patients into a group of extensive metabolizers (*1*1/*1*1) or even ultrarapid metabolizers 37.2% (*1*1/*1*17 and *1*1/*17*17); only smaller numbers of patients were intermediate or poor metabolizers (17.1% or 1.4%, respectively). We concluded that the most common loss-of-function CYP2C19*2 and gain-of-function CYP2C19*17 variants should be examined in patients with GERD before PPI pharmacotherapy is prescribed. Selection of adequate drugs and their proper dosing may contribute to improve patients’s life quality and prevent the progression to more severe GERD conditions such as BE and EAC.
ER  -

BOŘILOVÁ LINHARTOVÁ, Petra, Ladislav BARTOŠ, Ladislava BARTOŠOVÁ, Adam KŘENEK, Jiří DOLINA, Filip MAREK, Zdeněk KALA and Lydie IZAKOVIČOVÁ HOLLÁ. Proton pump inhibitors therapy and cyp2c19 gene variability in Czech patients with gastroesophageal reflux disease: pilot study. In \textit{67. Česko-Slovenské Farmakologické dni}. 2017. ISSN~1337-6853.

Detailed Information on Publication Record